5:57 PM
 | 
Jan 24, 2013
 |  BC Extra  |  Company News

FDA expands Avastin label

FDA approved a label expansion for Avastin bevacizumab from Genentech Inc. to include second-line treatment in combination with an irinotecan- or oxaliplatin-based chemotherapy regimen in patients with metastatic colorectal cancer (mCRC)...

Read the full 143 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >